007570 — Ilyang Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapSucker Stock

Annual cashflow statement for Ilyang Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS/A	ARS/A	ARS/A	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	14,752	19,806	-2,030	10,508	7,133
Depreciation
Non-Cash Items	4,937	-3,724	17,806	3,270	-5,640
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	20,513	-21,966	-13,128	-17,987	2,204
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	51,429	5,883	14,619	5,615	12,041
Capital Expenditures	-14,679	-3,958	-6,832	-40,623	-10,437
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	8.24	28,121	-4,683	3,448	3,212
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-14,671	24,163	-11,516	-37,175	-7,225
Financing Cash Flow Items	-31,524	184	-22	-0.559	28.6
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-36,632	-31,996	-6,978	32,240	14,617
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	125	-2,115	-3,759	881	19,359